Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Algeta Appoints Dr Andreas Menrad as CSO

Published: Monday, August 19, 2013
Last Updated: Monday, August 19, 2013
Bookmark and Share
Dr Menrad will be responsible for developing and executing the Company’s research strategy.

Algeta ASA has announced the appointment of Dr Andreas Menrad as Chief Scientific Officer (CSO) and member of the executive management team.

In this newly created role, Dr Menrad will be responsible for developing and executing the Company’s research strategy, including its Targeted Thorium Conjugate (TTC) platform. He will lead a rapidly growing and highly experienced R&D team.

Dr Menrad will report directly to Andrew Kay, Algeta’s President & CEO, and takes up his position immediately.

Dr Menrad brings more than 20 years of experience in the pharmaceutical and biotech industry, with a strong background in oncology therapeutic development.

He joins Algeta from Ablynx NV, where he was CSO. Prior to this, Dr Menrad spent five years at Genzyme (Sanofi) in Cambridge (UK), where most recently he held the role of General Manager and Vice President of Antibody Therapeutics.

Before that, he spent 15 years at Schering AG in senior research roles focused on oncology and antibody engineering. He is an author on more than 30 patents and more than 25 peer-reviewed publications.

Dr Menrad received his PhD in Immunology from the University of Stuttgart and conducted post-doctoral research at the Wistar Institute Cancer Center (Philadelphia, PA, USA).

With the appointment of Dr Menrad, Dr Thomas Ramdahl, the Company’s Executive Vice President will become Algeta’s Chief Operating Officer (COO) with responsibilities for key aspects of the Company’s European operations, its global manufacturing assets as well as the intellectual property portfolio.

Andrew Kay, Algeta’s President & CEO, said: “Andreas brings a wealth of complementary skills and experience to Algeta from his successful career in therapeutic research and development. We are confident that, in this key strategic leadership role, he will guide the development and direction of our research team as we seek to create a pipeline of development candidates. I would also like to congratulate Thomas on his appointment as Algeta’s COO, a new position that reflects the Company’s commercial evolution and our global manufacturing capabilities.”

Andreas Menrad, Algeta’s Chief Scientific Officer, added: “Algeta has an exceptional opportunity to establish a leading position in the field of targeted cancer therapeutics, including via its unique thorium-227 alpha-pharmaceutical payload. I am excited to join the Company at a time of significant momentum and I look forward to working to further develop and advance Algeta’s world-class technologies and capabilities.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Algeta Celebrates the Opening of Commercial Production Facility for Xofigo®
Official opening of new facility at the Institute for Energy Technology (IFE) in Kjeller, Norway.
Friday, June 21, 2013
Algeta Announces First Sale of Xofigo® in the United States
First sale triggers EUR 50 million milestone payment from Bayer.
Thursday, May 30, 2013
Algeta: FDA Approves Xofigo (radium-223 dichloride)
Xofigo shown in a pivotal phase III trial to significantly improve overall survival.
Friday, May 17, 2013
Algeta’s Partner Bayer Submits Radium-223 for EU Marketing Authorization
Submission to trigger €50 million milestone payment to Algeta.
Monday, April 22, 2013
Algeta Elects New Non-executive Members
Hilde Furberg and Paolo Pucci elected as new members of Algeta’s Board of Directors.
Friday, April 12, 2013
Algeta Initiates New Oncology Research Program to Conjugate Thorium-227 to Epratuzumab
CD22 is a well-validated target for hematological cancers.
Tuesday, January 29, 2013
Algeta and Ablynx Enter Into a Research Collaboration
Collaboration to evaluate the potential of novel alpha-pharmaceuticals comprising thorium-227 conjugated to tumor-targeting Nanobodies®.
Thursday, November 22, 2012
Algeta and Sanofi Extend Research Collaboration
Collaboration is focused on evaluating thorium-conjugated tumor-targeting antibody.
Monday, October 15, 2012
New Analyses from Phase III ALSYMPCA Trial Presented at ESMO 2012
Radium-223 dichloride (Alpharadin) was significantly superior to placebo in health-related quality of life (QOL) measures.
Monday, October 01, 2012
Updated Phase III Data Confirm Overall Survival Benefit of Alpharadin in Men with CRPC
Submissions seeking marketing approval in US & Europe expected in 2H 2012.
Monday, June 04, 2012
Jeffrey W. Albers Appointed President of Algeta US
Mr. Albers will join Algeta’s executive management team and takes up his position immediately.
Tuesday, January 17, 2012
Algeta Awarded Grant to Develop Targeted Thorium Conjugates
Company has been awarded a NOK 10.5 million grant from the Research Council of Norway.
Tuesday, January 03, 2012
Algeta Appoints Mike Booth as Senior Vice President, Communications and Corporate Affairs
New role created to enhance Algeta's global corporate communications and investor relations activities.
Friday, December 30, 2011
Alpharadin Significantly Improves Overall Survival for CRPC Patients with Bone Metastases
First presentation of full ALSYMPCA phase III data as part of Presidential Session featuring Best and Late-Breaking Abstracts at 2011 EMCC.
Monday, October 10, 2011
Algeta Signs License with Affibody for Tumor-Targeting Molecules
Algeta gains access to two proprietary Affibody® molecules for use in cancer therapy.
Tuesday, August 30, 2011
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Connectome Map More Than Doubles Human Cortex’s Known Regions
Researchers at NIH have developed software that automatically detects the “fingerprint” of each of these areas in an individual’s brain scans.
Discovered Through ‘Big Data’ Analysis
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
Human Stem Cells to Rapidly Generate Bone, Heart Muscle
A new study shows that combining positive and negative signals can quickly and efficiently steer stem cells down complex developmental pathways to become specialized tissues that could be used in the clinic.
New Mechanism of Tuberculosis Infection
Researchers at UTSW Medical Center have identified a new way that tuberculosis bacteria get into the body, revealing a potential therapeutic angle to explore.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer and that, when deleted in the lungs of mice, prevents the cancer from forming.
Eliminating Doubt in Criminal Investigations
New ASU certificate to help curb error, misunderstanding in the quest for justice.
Determination of 13 Organic Toxicants in Human Blood
Researchers have utilised liquid-liquid extraction coupling HPLC-MS/MS to identify and quantify organic toxicants in human blood.
A Novel Cell Culture Model For Forensic Biology Experiments
Researchers have developed a new cell culture model which provides an efficient research tool in forensic biology.
Rhino DNA Bank Aids Anti-Poaching Fight
At the University of Pretoria's Veterinary Genetics Laboratory (VGL) at Onderstepoort, Dr Cindy Harper and her team have developed a ground-breaking technique to collect and catalogue DNA from rhinos and rhino horns.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!